TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01321619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daflon
Description: Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varicell placebo
Description: Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
Study: NCT00568815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab combined with ESHAP
Description: Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
Study: NCT04120584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forma Eye Applicator
Description: Eligible subjects will receive up to 3 treatments (2-3 weeks interval) with the Forma Eye Applicator according to the study protocol.~The subject will return for 3 follow up visits: four weeks (4wk FU), 12 weeks (12wk FU), twenty-four weeks (24wk FU) after the last treatment.
Study: NCT03873636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stimulation via noninvasive brain stimulation systems
Description: Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stimulation via noninvasive brain stimulation systems
Description: Active (at or below 2mA) stimulation targeting brain regions engaged in task-switching and dual-tasking for 30-40 minutes. Local IRB has determined the Soterix, Neuroelectrics, \& Halo devices to be non-significant risk (NSR) devices via abbreviated investigational device exemption (IDE) procedure.
Study: NCT03309007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
Study: NCT00217516

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01847261

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Dairy Protein Blend

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Positive Control (Dairy Whey Protein)
Study: NCT02950012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: OPTI-BIOME™ Bacillus subtilis MB40

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03231215

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone + plain Bupivacaine injected epidurally.
Study: NCT03710421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CS1-CAR T Therapy
Description: Undergo CS1-CAR T therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis
Study: NCT03495934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pracinostat
Description: \[14C\]-pracinostat
Study: NCT04289779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib 40 mg orally daily for 3 cycles
Study: NCT03884491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine SLA
Description: 5-25 mg of sublingual formulation A of vortioxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine SLB
Description: 5-25 mg of sublingual formulation B of vortioxetine
Study: NCT04289779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg IV every 3 weeks for 3 cycles

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Patients will receive three cycles of treatment prior to cystectomy unless they discontinue treatment for unacceptable toxicity or progressive disease by RECIST v1.1 or withdraw consent.
Study: NCT01605357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induced, sustained hypernatremia using hypertonic saline
Description: Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.~Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.~Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.~Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.~Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care (hypertonic saline and mannitol; serum sodium)
Description: Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium \< 135 mmol/L) is to be corrected at the discretion of the provider.
Study: NCT02822053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US-guided laser ablation for refractory neoplasms
Study: NCT02146131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard FB with fluoroscopy
Description: Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: R-EBUS with ultrathin bronchoscope
Description: Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
Study: NCT00962871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc/week for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc/week for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir
Description: 300mg po daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: 300mg po daily for 2 weeks
Study: NCT01445847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
Study: NCT01987466

Intervention type: BIOLOGICAL
Intervention: Serum NGAL level
Description: Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
Study: NCT03321071

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Summer Learners
Description: Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.~Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.~Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.~Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 21st Century Summer Learning Center
Description: Children in this condition will attend a 21st Century Summer Learning Program.
Study: NCT00204529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon-alpha-2a

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: interferon-alpha-2a
Study: NCT04421404

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma (CCP)
Description: COVID-19 Convalescent Plasma (CCP) is a form of passive antibody therapy that involves the administration of anti-SARS-CoV-2 antibodies to a susceptible individual for the purpose of preventing or treating the infectious disease it causes. Convalescent plasma for this trial will be obtained from Vitalant (or American Red Cross if necessary). Patients identified as having recovered from COVID-19 will serve as potential donors. Potential donors will be screened using an anti-SARS-CoV-2 serologic assay and antibody levels will be determined.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard plasma will be obtained from Vitalant (or American Red Cross if necessary) and will be either collected prior to 12/1/2019 or tested and confirmed to be negative for anti-SARS-CoV-2.
Study: NCT00707993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
Study: NCT00827814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride
Description: Dutasteride 0.5 mg od.
Study: NCT01298843

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline fosamil
Description: Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
Study: NCT02712996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, 20-70 mg, each morning for 6 weeks.
Study: NCT03623438

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administered acupressure group
Description: Subjects in the self-administered acupressure group will attend an acupressure training course (2 sessions, 2 hours each) to learn self-administered acupressure, which will then be performed every night for 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene education (SHE) group
Description: Subjects in the comparison group will receive sleep hygiene education (2 sessions, 2 hours each, same as the treatment group) and be reminded to follow the sleep hygiene practice daily for 4 weeks.
Study: NCT01773928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)
Study: NCT03231215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone + plain Bupivacaine injected epidurally.
Study: NCT02487888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded to Genetic Testing Results
Description: The physicians of this group of patients will be unblinded to the results of the genetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded to Genetic Testing Results
Description: The physicians of this group of patients will be unblinded to the results of the genetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded to Genetic Testing Results
Description: The physicians of this group of patients will be unblinded to the results of the genetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded to Genetic Testing Results
Description: The physicians of this group of patients will be unblinded to the results of the genetic testing.
Study: NCT01773928

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VCIV manufactured with the current manufacturing process (VCIV current)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®, licensed trivalent influenza vaccine (TIV)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone®, licensed trivalent influenza vaccine (TIV)
Study: NCT03100266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Lactobacillus rhamonosus GG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inactive capsules
Description: Placebo
Study: NCT02039830

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group physiotherapy
Description: Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual one-on-one physiotherapy
Description: Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
Study: NCT01381770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: platelet-derived repairing factors
Description: autologous platelet lysate injection within 24 hours from lesion
Study: NCT05795270

Intervention type: OTHER
Intervention: Treatment
Description: Nocturnal ventilotherapy, positional therapy and oro-mandibular devices
Study: NCT01103856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Mentor Intervention
Description: The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: HIV transmission risk reduction
Description: The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
Study: NCT02227810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation (high frequency)
Description: Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrical stimulation (low frequency)
Description: Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham group
Description: Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
Study: NCT03069378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec (T-VEC)
Description: Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
Study: NCT02132572

Intervention type: DEVICE
Intervention: BIOCELL™ Textured 410 Implant
Description: Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
Study: NCT03884491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine SLC
Description: formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg
Study: NCT02487888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unblinded to Genetic Testing Results
Description: The physicians of this group of patients will be unblinded to the results of the genetic testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded to Genetic Testing Results
Description: The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded to Genetic Testing Results
Description: The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded to Genetic Testing Results
Description: The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded to Genetic Testing Results
Description: The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blinded to Genetic Testing Results
Description: The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
Study: NCT02904187

Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography (PET)

Intervention type: OTHER
Group type: OTHER
Intervention: Positron Emission Tomography (PET)
Study: NCT03748758

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug: OP0201
Description: Drug OP0201

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug: OP0201
Description: Drug OP0201

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Placebo
Study: NCT01018966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
Study: NCT00745836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: statin
Study: NCT02726152

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polymer clips for closure of the appendiceal stump
Description: Application of polymer clips to the appendiceal stump
Study: NCT02904187

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram (EEG)

Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalogram (EEG)
Study: NCT01208571

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booster session
Description: Motivational interview
Study: NCT02705768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
Study: NCT02389686

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTRABEAM (Carl Zeiss, Oberkochen, Germany)
Description: Boost with 16 Gy during NSM for nipple-areola complex (NAC)
Study: NCT03768141

Intervention type: PROCEDURE
Intervention: Liver surgery
Description: All indications (including benign and living donor resections), all co-morbidities, open, laparoscopic or robotic, single wedge resections to extended liver resections, single or two-stage hepatectomies, procedures with liver volume enhancement such as portal vein embolization (PVE), portal vein ligation (PVL), Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS), resections involving cold perfusion (ex-situ and ante-situ)
Study: NCT01094951

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ENGAGE
Description: During Stage 2, investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred community-based mental health services.
Study: NCT05322057

Intervention type: DRUG
Intervention: Darvadstrocel
Description: Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells around the fistula opening and around the fistula tract